Compare HBCP & FDMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HBCP | FDMT |
|---|---|---|
| Founded | 1908 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 434.2M | 391.8M |
| IPO Year | 2008 | 2020 |
| Metric | HBCP | FDMT |
|---|---|---|
| Price | $57.08 | $11.19 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 9 |
| Target Price | ★ $63.50 | $30.33 |
| AVG Volume (30 Days) | 22.2K | ★ 911.8K |
| Earning Date | 10-20-2025 | 11-10-2025 |
| Dividend Yield | ★ 2.17% | N/A |
| EPS Growth | ★ 24.56 | N/A |
| EPS | ★ 5.62 | N/A |
| Revenue | ★ $145,087,000.00 | $120,000.00 |
| Revenue This Year | $2.60 | $21,181.08 |
| Revenue Next Year | $3.27 | $162.43 |
| P/E Ratio | $10.18 | ★ N/A |
| Revenue Growth | 11.42 | ★ 605.88 |
| 52 Week Low | $39.59 | $2.24 |
| 52 Week High | $61.07 | $12.34 |
| Indicator | HBCP | FDMT |
|---|---|---|
| Relative Strength Index (RSI) | 64.56 | 54.86 |
| Support Level | $55.20 | $9.92 |
| Resistance Level | $57.31 | $11.89 |
| Average True Range (ATR) | 1.18 | 0.83 |
| MACD | 0.34 | -0.04 |
| Stochastic Oscillator | 95.71 | 64.47 |
Home Bancorp Inc is engaged in attracting deposits from the public and using those funds to invest in loans and securities. The principal sources of funds are customer deposits, repayments of loans, repayments of investments and funds borrowed from outside sources such as the Federal Home Loan Bank of Dallas. These funds are used for the origination of loans, including one-to-four-family first mortgage loans, home equity loans, and lines, commercial real estate loans, construction and land loans, multi-family residential loans, commercial and industrial loans, and consumer loans.
4D Molecular Therapeutics Inc is a clinical-stage gene therapy company engaged in the development of product candidates using targeted and evolved AAV vectors. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-125, 4D-110, and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector) 4D-310.